Who Generates Higher Gross Profit? Pfizer Inc. or Exelixis, Inc.

Pfizer Inc. vs. Exelixis, Inc.: A Decade of Gross Profit Analysis

In the competitive landscape of the pharmaceutical industry, understanding which companies generate higher gross profits can provide valuable insights into their market dominance and operational efficiency. Over the past decade, Pfizer Inc. has consistently outperformed Exelixis, Inc. in terms of gross profit. From 2014 to 2023, Pfizer's gross profit peaked in 2022, reaching approximately 66 billion, while Exelixis saw its highest gross profit in 2023, at around 1.76 billion. This stark contrast highlights Pfizer's robust market position, generating nearly 40 times more gross profit than Exelixis on average. However, Exelixis has shown impressive growth, with its gross profit increasing by over 7,500% from 2014 to 2023. This growth trajectory suggests a promising future for Exelixis, as it continues to expand its market presence and operational capabilities.